Bio-Techne posts revenue gains in Q3

By The Science Advisory Board staff writers

May 6, 2021 -- Bio-Techne reported strong growth in revenues for its third quarter (end-March 31), thanks largely to sales in its protein analysis business.

For the third quarter, Bio-Techne posted revenue of $243.6 million, up 22% compared to last year, with foreign currency exchange having a favorable effect of 3%.

For the first nine months of fiscal year 2021, the company reported revenue of $672 million, up 17% compared to last year.

Additionally, the company reported net sales of its protein sciences segment, which provides an array of platforms useful in various areas of protein analysis, were $185.6 million, a record increase of 28% from $145.5 million for the third quarter of fiscal 2020, according to a release.

908 Devices, Bio-Techne partner on protein characterization workflow
908 Devices and Bio-Techne are collaborating to develop an extended workflow solution for protein characterization.
Bio-Techne releases new in situ hybridization assay
Bio-Techne has released DNAscope Assay, a new in situ hybridization assay kit.
Bio-Techne licenses antibody to Xencor
Bio-Techne has licensed an antibody to Xencor for therapeutic development.
Bio-Techne launches Abby automated western system
Bio-Techne announced that its brand ProteinSimple has released Abby, its next-generation chemiluminescence system that automates traditional western blotting.
Luminary licenses TcBuster CAR T tech from Bio-Techne
Luminary Therapeutics has signed a license agreement with Bio-Techne for the use of its TcBuster chimeric antigen receptor (CAR) T technology for the...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter